Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lobradimil · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Lobradimil | DRUG | - |
| Amphotericin B | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Up to 1 mg/kg amphotericin B for the current episode of cryptococcal meningitis. Patients must have: * HIV infection. * Acute cryptococcal meningitis. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or condit...
Lobradimil is an investigational small molecule being studied for the treatment of cryptococcal meningitis, a serious fungal infection of the membranes surrounding the brain and spinal cord. It is being developed by Alkermes plc (ticker: ALKS) and is currently in Phase 1 clinical development.
The specific molecular target of Lobradimil has not been disclosed in available information. It is a small molecule being evaluated for its potential role in treating cryptococcal meningitis, particularly in patients with HIV infections, but its mechanism of action is not publicly detailed.
Lobradimil is being developed by Alkermes plc, a biopharmaceutical company traded on the stock exchange under the ticker symbol ALKS. The company is conducting clinical research on this investigational drug for the treatment of cryptococcal meningitis.
Lobradimil is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, and no active trials are currently listed for this drug.
Lobradimil has been studied in one completed clinical trial with the identifier NCT00002316. This Phase 1 trial evaluated the safety and effectiveness of RMP-7 plus amphotericin B in patients with HIV and cryptococcal meningitis. The trial was conducted in the United States and enrolled adults aged 18 years and older.
Yes, Lobradimil is also known as RMP-7. In the clinical trial NCT00002316, the drug is referred to as RMP-7, and it was studied in combination with amphotericin B for the treatment of cryptococcal meningitis in patients with HIV infections.